MEET THE TEAM

Please meet the people behind our company, led by Tom Wiggans, with additional industry veterans from Connetics, Peplin, Stiefel and Gilead.

TECHNOLOGY SPOTLIGHT

Cimzia®, our lead product candidate, is a PEGylated, humanized antigen-binding mAb fragment TNF inhibitor in development for the treatment of moderate-to-severe plaque psoriasis.

Dermira Prices Initial Public Offering

REDWOOD CITY, Calif., October 2, 2014 – Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a price to the public of $16.00 per share. The… View Article

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients.